Myriad Genetics Company Profile (NASDAQ:MYGN)

Myriad Genetics trades on the NASDAQ under the ticker symbol "MYGN."

Myriad Genetics, Inc. (NASDAQ:MYGN) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.03. The business had revenue of $196.90 million for the quarter, compared to analysts' expectations of $188.89 million. Myriad Genetics had a return on equity of 10.53% and a net margin of 4.26%. View Myriad Genetics' Earnings History.

Myriad Genetics updated its fourth quarter earnings guidance on Tuesday, May, 2nd. The company provided earnings per share (EPS) guidance of $0.26-0.28 for the period, compared to the Thomson Reuters consensus estimate of $0.26. The company issued revenue guidance of $192-194 million, compared to the consensus revenue estimate of $188.50 million.

13 analysts have issued twelve-month price targets for Myriad Genetics' shares. Their predictions range from $16.00 to $32.00. On average, they expect Myriad Genetics' stock price to reach $21.83 in the next twelve months. View Analyst Ratings for Myriad Genetics.

Here are some recent quotes from research analysts about Myriad Genetics stock:

• 1. According to Zacks Investment Research, "Over the last three months, Myriad Genetics has been trading above the broader Medical - Biomedical and Genetics industry. The company saw strong growth in EndoPredict test revenues and sequential growth in hereditary cancer volumes in the last reported quarter. Recently, Myriad’s companion diagnostic program received a major boost in a new cancer indication, in collaboration with AstraZeneca. We are also optimistic in regard to Myriad’s collaboration with BeiGene for development of companion diagnostics. On the flip side, gross margin scenario is disappointing. Also the company’s narrowing bottom line guidance for fiscal 2017 is discouraging, indicating a looming concern ahead. Currency fluctuations and stiff competition are other major headwinds for the company." (7/17/2017)
• 2. Cowen and Company analysts commented, "The FDA approved Tesaro's niraprarib (Zejula) yesterday. This approval was not limited to mutational status, and therefore does not require MYGN's myChoice HRD test. This outcome is consistent with our thoughts since last June, and as a result has limited impact to our MYGN financial forecast." (3/28/2017)
• 3. UBS AG analysts commented, "MYGN reported FY4Q16 earnings on Tuesday. Reported sales of $187m were roughly in-line with our estimate of $187m and consensus estimates of $188m. Adjusted EPS of $0.36 was below both our estimate of $0.38 and consensus estimates of $0.37. Most importantly, for FY2017, management guided to sales of $740m – $760m and adj. EPS of $1.00 – $1.10 compared to consensus forecasts of $790m and $1.77. We have lowered our FY2017 EPS forecast by 43%." (8/10/2016)

Some companies that are related to Myriad Genetics include Intercept Pharmaceuticals (ICPT), Globus Medical (GMED), Juno Therapeutics (JUNO), Sage Therapeutics (SAGE), Cantel Medical Corp. (CMD), Insulet Corporation (PODD), INC Research Holdings (INCR), LivaNova PLC (LIVN), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), HealthEquity (HQY), Wright Medical Group N.V. (WMGI), Penumbra (PEN), Hutchison China MediTech Limited (HCM), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), Intrexon Corporation (XON) and China Biologic Products (CBPO).

Myriad Genetics' management team includes the folowing people:

• John T. Henderson M.D., Independent Chairman of the Board
• Mark C. Capone, President, Chief Executive Officer, Director
• Walter M. Gilbert Ph.D., Independent Vice Chairman of the Board
• R. Bryan Riggsbee CPA, Chief Financial Officer, Treasurer
• Virginia C. Drosos, President of Assurex Health, Inc.
• Alexander Ford, President of Myriad Genetic Laboratories, Inc.
• Ralph L. McDade Ph.D., President of Myriad RBM, Inc
• Bernard F. Tobin, President of Crescendo Bioscience, Inc
• Richard M. Marsh Esq., Executive Vice President, General Counsel, Secretary
• Gary A. King, Executive Vice President - International Operations

Myriad Genetics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (2.24%), Russell Investments Group Ltd. (1.58%), CWM LLC (0.79%), Bank of Montreal Can (0.36%), BB&T Corp (0.31%) and Adams Asset Advisors LLC (0.13%). Company insiders that own Myriad Genetics stock include Alexander Ford, Gary A King, Heinrich Dreismann, Jerry S Lanchbury, John T Henderson, Mark Christopher Capone, Ralph L Mcdade, Richard M Marsh, S Louise Phanstiel and Walter Phd Gilbert. View Institutional Ownership Trends for Myriad Genetics.

Myriad Genetics' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., Strs Ohio, Capstone Asset Management Co. and Creative Planning. View Insider Buying and Selling for Myriad Genetics.

Myriad Genetics' stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Hartford Investment Management Co., BB&T Corp, State of Alaska Department of Revenue, Eqis Capital Management Inc., LeJeune Puetz Investment Counsel LLC, Aperio Group LLC and CWM LLC. Company insiders that have bought Myriad Genetics stock in the last two years include John T Henderson, Mark Christopher Capone and Ralph L Mcdade. View Insider Buying and Selling for Myriad Genetics.

Shares of Myriad Genetics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Myriad Genetics stock can currently be purchased for approximately $23.74.